The application for full approval is “in parallel” with emergency use, said Berkeley Phillips, medical director of Pfizer UK, in a briefing.
He said regulators will review the same data provided for the emergency use by Pfizer and its partner and BioNTech for the full approval. He did not say when that decision may come.
Deliveries to Britain could not have started until the regulators had given their go ahead, he said. Regulators will assess each batch of the vaccine for quality.